Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.61 |
| ▸ | ESR1 | P03372 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | DRD1 | P21728 | 1/20 | 0.48 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexestrol Diphosphate SCHEMBL62206 | 1.00 | BLM (0.61) | BLMESR1HIF1ACYP2C19LMNA | |
| SCHEMBL209725 | 0.93 | ESR1 (0.61) | BLMESR1HIF1ACYP2C19LMNA | |
| SCHEMBL209724 | 0.93 | ESR1 (0.61) | BLMESR1HIF1ACYP2C19LMNA | |
| Diethylstilbestrol Diphosphate SCHEMBL8153893 | 0.85 | BLM (0.70) | BLMESR1HIF1ACYP2C19LMNA | |
| SCHEMBL12716935 | 0.84 | BLM (0.54) | BLMCYP2C19MAPTTDP1SRC | |
| SCHEMBL4254509 | 0.81 | ESR1 (0.54) | BLMESR1HIF1ACYP2C19LMNA | |
| SCHEMBL223266 | 0.79 | SRC (0.54) | BLMLMNASRCCA1CA2 | |
| SCHEMBL27342545 | 0.77 | SRC (0.52) | BLMLMNASRCCA1CA2 | |
| SCHEMBL329313 | 0.77 | SRC (0.75) | BLMCYP2C19CYP3A4SRCCA1 | |
| SCHEMBL924938 | 0.76 | SRC (0.56) | BLMCYP2C19SRCCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186486-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-06-12 | — | — | US | disclosed |
| WO-2025068966-A2 | SYNERGISTIC DENTIFRICE (ORAL) COMPOSITION, FORMULATION AND PREPARATION METHOD AND APPLICATION THEREOF | RAI BALWANT (IN) | 2025-04-03 | — | — | WO | disclosed |
| EP-4493166-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | Baylor College of Medicine (US) | 2025-01-22 | — | — | EP | disclosed |
| WO-2023177870-A1 | POTENTIATION OF DURABLE ANTITUMOR IMMUNITY BY MULTIFACTORIAL IMMUNE MODULATION | BAYLOR COLLEGE OF MEDICINE (US) | 2023-09-21 | — | — | WO | disclosed |
| CN-113774106-B | Method for detecting genotoxicity by utilizing 3D liver cell in-vitro micronucleus cytology | 上海益诺思生物技术股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-111909097-B | Method for purifying bendamustine hydrochloride | 南京力成药业有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20160008376-A1 | Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | US | disclosed |
| WO-2016005599-A1 | COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS | BIOCOPEA LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| CN-103492590-A | Circulating biomarkers | CARIS LIFE SCIENCES LUXEMBOURG HOLDINGS S A R L | 2014-01-01 | — | — | CN | disclosed |
| US-20090048667-A1 | Controlled Drug-Release Composition and Drug-Releasable Medical Device | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2009-02-19 | — | — | US | disclosed |
| US-5330767-A | Sustained release microcapsule | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-07-19 | — | — | US | disclosed |
| EP-0190833-B1 | METHOD FOR PRODUCING MICROCAPSULE | Takeda Chemical Industries, Ltd. (JP) | 1991-03-27 | — | — | EP | disclosed |
| US-4954298-A | Method for producing microcapsule | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-09-04 | — | — | US | disclosed |
| EP-0190833-A2 | Method for producing microcapsule | Takeda Chemical Industries, Ltd. (JP) | 1986-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048667-A1 | Controlled Drug-Release Composition and Drug-Releasable Medical Device | LDLR, SRR, PLAUR | BLM 1668/4885ESR1 3645/4885HIF1A 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.